Medical treatment of peptic ulcer diseases has gained widespread use since the introduction of H2-receptor blockers in the late 1970s. Initially, worries were expressed regarding a possible carcinogenic effect of cimetidine, when case reports of gastric carcinoma in cimetidine treated patients appeared. 2 Epidemiological studies have indeed confirmed an increased occurrence of gastric cancer and other abdominal cancers shortly after start of cimetidine use. The excess risk levels off in the following years and is undoubtedly the result of selection of patients with an unrecognised malignancy at the time of commencement of peptic ulcer treatment.3" It has been debated whether or not to use medical treatment for ulcer like symptoms, without a full diagnostic procedure being performed.78 Finally, the safety of long term maintenance therapy to prevent peptic ulcer recurrence has been discussed but not fully evaluated because barely 15 years have elapsed since their introduction world wide.9 '0 A small Danish study showed that in 1984, maintenance therapy with cimetidine was already common. A third of all prescriptions for cimetidine were given to patients with unproven peptic ulceration, and furthermore, half of these had used the drug for more than five years. ' It has been shown that the therapeutic hypochlorhydria which is the primary action of these drugs is associated with increased gastric bacterial growth, reduction of nitrate to nitrite, and increased concentration of carcinogenic N-nitroso compounds in the gastric juice. ' The 1977-81 material is thought to be essentially complete, except for the exclusion of 12% who had a previous history of malignancy or had undergone gastric surgery or who were given the drug for another diagnosis than a peptic ulcer related disease. The completeness of the 1989-90 material is more difficult to evaluate because the drugs in this period were available over the counter. The National Board of Health estimates that the use of peptic ulcer drugs without application for partial compensation amounts to some 10% of the total use. '8 The prevalence of cimetidine use around 1979 -that is, the proportion of the population using cimetidine anytime in the period 1977-81 -was calculated in 10 year age groups using population data of 1 January 1980, and the prevalence of use of ulcer drugs around 1989 was similarly calcu- (Table III) . Long term use was most frequent among those who were in their 50s and 60s in 1977-81 (37%). Among the long term users, the majority of the 1989-90 applications were for H2-receptor blockers (88%). Omeprazole (6%) and other drugs (mainly antacids, bismuth subcitrate and sucralfate) (6%) were less commonly applied for. The pattern of use of different drugs among all applicants in 1989-90 were 80% H2-receptor blockers, 7% omeprazole and 13% other drugs. Analysis of risk factors for longterm use did not reveal any strong determinants other than age (Table IV) . The highest risk of becoming a long term user was seen for those aged 50-69 years in 1977-81. No effect was seen for sex. The probability of becoming a long term user was higher for duodenal ulcer patients than for gastric ulcer patients, and higher for those who had the initial diagnoses based on a radiographic examination rather than endoscopy.
The relative risk of gastric cancer in cimetidine users decreased among men from 8 1 in the first year of follow up to a non-significant 13 [7] [8] [9] [10] [11] years after first use of cimetidine (Table V) . In women, however, the data suggested an increased risk of gastric cancer after seven years where the relative risk was 4-7 (1 7-10 3) after an initial decrease from 12 6 in the first year to 1I9 [4] [5] [6] [7] The Danish data show that the potent proton pump inhibitor omeprazole is being commonly used (up to 10%), especially among the younger long term users.
The shift in age distribution from a median age at 55 years in the 1977-81 users to 63 years in the 1989-90 users is perhaps the most important finding of the present study. Not only does the use of peptic ulcer drugs increase, but the drugs are increasingly being used by the oldest users in the population. A slight shift in the age distribution would be expected because of the increasing prevalence of non-operated peptic ulcer patients in the population. Similarly, the increasing use of non-steroidal anti-inflammatory drugs may have caused an increasing number ofpeptic ulcer cases in the older age groups.23 These effects can hardly explain a shift in median age from 55 years to 63 years in only a decade, however. A smaller part of the total use of peptic ulcer drugs are being prescribed for diseases other than peptic ulcer -for example, oesophagitis and ZollingerEllison syndrome. Compared with peptic ulcer, these diseases are rare and not particularly prevalent among the oldest in the population. The most important change in the pattern of use of peptic ulcer drugs (especially H2-receptor blockers) is probably that the drugs are increasingly being used to treat non-ulcer dyspepsia and other unspecific gastrointestinal discomfort for which H2-receptor blockers are of little value. 24 An initial diagnosis of duodenal ulcer and the method of diagnosis being a radiographic examination seems to increase the risk of becoming a long term user of ulcer drugs. Taking age into account does not lead to estimates closer to unity, and hence the effects can not be attributed to confounding. It may be that the effect of diagnosis is real and that duodenal ulcer is more persistent than gastric ulcer, or it may be that a higher proportion of gastric ulcer patients have been operated upon in the time between the two periods of registrations of drug use. Regarding the method ofdiagnosis, it is hard to imagine that the apparent effect is real. It may be that different subgroups of patients with differences in prognosis have been selected into the two diagnostic procedures.
The follow up for morbidity of gastric cancer shows increased risks in the years after starting cimetidine treatment. This phenomenon has been discussed above and is not the result of a carcinogenic effect of cimetidine but undoubtedly reflects that some patients with gastric cancer were thought to have peptic ulcer and therefore treated with cimetidine. If cimetidine (or the hypochlorhydric condition it creates) is in fact carcinogenic to the gastric mucosa, gastric cancer incidence should be expected to increase only after a period of time after initiation of treatment. The pattern seen among women suggests the possibility of such an effect, but the low number of cases occurring seven years after start ofcimetidine use or longer (only six) and the absence of any effect in men speak against the interpretation of the association as being casual. Clearly, the situation warrants further follow up for cancer morbidity in this cohort.
